By the Doktorly editorial team · Medically reviewed by the Doktorly medical team · Last updated: 27 October 2026
Liraglutide was the first GLP-1 ingredient approved in the EU explicitly for weight reduction – long before Ozempic made the headlines. Today it is regarded as the "reduced-strength" option: somewhat weaker in effect, but by far the longest established.
Both products contain liraglutide from Novo Nordisk. For losing weight, Saxenda is the relevant product; Victoza would be an off-label use.
Liraglutide stays active in the body for only about 13 hours – too short for a weekly injection. That is why it is injected once daily. The advantage: the effect can be dosed finely and reduced quickly if side effects occur. The disadvantage: daily injections and higher pen consumption.
In the SCALE trial, participants on liraglutide 3 mg lost on average about 8 % of their weight over one year, versus about 2.6 % on placebo. The Lancet: SCALE (2015). Newer ingredients exceed that: semaglutide reached about 15 % in comparable designs, tirzepatide even about 20 %.
Saxenda can still make sense if you:
The full comparison of all ingredients is available here: weight-loss injections compared.
Victoza is approved only for type 2 diabetes. Prescribing it for weight loss would be off-label – the 3 mg product Saxenda is the one intended for weight management.
About five weeks: the dose rises weekly from 0.6 mg up to the target dose of 3.0 mg daily.
Roughly 330–400 € for self-payers, since it is injected daily and more pen content is used.
Weight regain is possible and was frequently observed in studies. Sustainable nutrition and exercise habits plus medical follow-up are important.